Antitumor effect of antiplatelet agents in gastric cancer cells: an in vivo and in vitro study

Jota Mikami, Yukinori Kurokawa, Tsuyoshi Takahashi, Yasuhiro Miyazaki, Makoto Yamasaki, Hiroshi Miyata, Kiyokazu Nakajima, Shuji Takiguchi, Masaki Mori, Yuichiro Doki

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: The antitumor effects of antiplatelet agents in gastric cancer cells are not well known. In this study, the possibility of gastric cancer treatment with an antiplatelet agent, mainly aspirin, was examined both in vivo and in vitro. Methods: For in vivo experiments, tumor-bearing mice were treated by an antiplatelet antibody or aspirin, and the tumor growth was compared. For in vitro experiments, human gastric cancer cell lines were used to confirm the cancer cell growth and inhibition by reducing the platelet count or using aspirin. We also examined several cytokines by using an ELISA assay and conducted microRNA microarray analysis of MKN-45 tumor cells to determine the influence of platelets or aspirin. Results: In vivo experiments showed that tumor growth was inhibited by halving the circulating platelet count by using an antiplatelet antibody or peroral daily aspirin. In vitro experiments showed that the proliferation rates of gastric cancer cell lines were increased after coincubation with platelets and that the effect was inhibited by aspirin. Although the expression of interleukin-6, platelet-derived growth factor, transforming growth factor-β, and prostaglandin E2 did not correlate with tumor growth inhibition by aspirin, seven microRNAs showed altered expression in cancer cells in response to coincubation with platelets or addition of aspirin. Cells transfected with mir-4670-5p showed a significant increase in proliferation compared to negative control cells. Conclusions: Our study showed that platelets increased the proliferation of gastric cancer cells and that this increase was inhibited by antiplatelet antibody or aspirin. Mir-4670-5p may play an important role in these responses.

Original languageEnglish
Pages (from-to)817-826
Number of pages10
JournalGastric Cancer
Volume19
Issue number3
DOIs
Publication statusPublished - Jul 1 2016
Externally publishedYes

Fingerprint

Platelet Aggregation Inhibitors
Aspirin
Stomach Neoplasms
Blood Platelets
Neoplasms
Growth
MicroRNAs
Platelet Count
Antibodies
In Vitro Techniques
Cell Line
Platelet-Derived Growth Factor
Transforming Growth Factors
Microarray Analysis
Dinoprostone
Interleukin-6
Enzyme-Linked Immunosorbent Assay
Cytokines

All Science Journal Classification (ASJC) codes

  • Oncology
  • Gastroenterology
  • Cancer Research

Cite this

Mikami, J., Kurokawa, Y., Takahashi, T., Miyazaki, Y., Yamasaki, M., Miyata, H., ... Doki, Y. (2016). Antitumor effect of antiplatelet agents in gastric cancer cells: an in vivo and in vitro study. Gastric Cancer, 19(3), 817-826. https://doi.org/10.1007/s10120-015-0556-2

Antitumor effect of antiplatelet agents in gastric cancer cells : an in vivo and in vitro study. / Mikami, Jota; Kurokawa, Yukinori; Takahashi, Tsuyoshi; Miyazaki, Yasuhiro; Yamasaki, Makoto; Miyata, Hiroshi; Nakajima, Kiyokazu; Takiguchi, Shuji; Mori, Masaki; Doki, Yuichiro.

In: Gastric Cancer, Vol. 19, No. 3, 01.07.2016, p. 817-826.

Research output: Contribution to journalArticle

Mikami, J, Kurokawa, Y, Takahashi, T, Miyazaki, Y, Yamasaki, M, Miyata, H, Nakajima, K, Takiguchi, S, Mori, M & Doki, Y 2016, 'Antitumor effect of antiplatelet agents in gastric cancer cells: an in vivo and in vitro study', Gastric Cancer, vol. 19, no. 3, pp. 817-826. https://doi.org/10.1007/s10120-015-0556-2
Mikami J, Kurokawa Y, Takahashi T, Miyazaki Y, Yamasaki M, Miyata H et al. Antitumor effect of antiplatelet agents in gastric cancer cells: an in vivo and in vitro study. Gastric Cancer. 2016 Jul 1;19(3):817-826. https://doi.org/10.1007/s10120-015-0556-2
Mikami, Jota ; Kurokawa, Yukinori ; Takahashi, Tsuyoshi ; Miyazaki, Yasuhiro ; Yamasaki, Makoto ; Miyata, Hiroshi ; Nakajima, Kiyokazu ; Takiguchi, Shuji ; Mori, Masaki ; Doki, Yuichiro. / Antitumor effect of antiplatelet agents in gastric cancer cells : an in vivo and in vitro study. In: Gastric Cancer. 2016 ; Vol. 19, No. 3. pp. 817-826.
@article{ff7681750fdb4b8a93fe323fc68df831,
title = "Antitumor effect of antiplatelet agents in gastric cancer cells: an in vivo and in vitro study",
abstract = "Background: The antitumor effects of antiplatelet agents in gastric cancer cells are not well known. In this study, the possibility of gastric cancer treatment with an antiplatelet agent, mainly aspirin, was examined both in vivo and in vitro. Methods: For in vivo experiments, tumor-bearing mice were treated by an antiplatelet antibody or aspirin, and the tumor growth was compared. For in vitro experiments, human gastric cancer cell lines were used to confirm the cancer cell growth and inhibition by reducing the platelet count or using aspirin. We also examined several cytokines by using an ELISA assay and conducted microRNA microarray analysis of MKN-45 tumor cells to determine the influence of platelets or aspirin. Results: In vivo experiments showed that tumor growth was inhibited by halving the circulating platelet count by using an antiplatelet antibody or peroral daily aspirin. In vitro experiments showed that the proliferation rates of gastric cancer cell lines were increased after coincubation with platelets and that the effect was inhibited by aspirin. Although the expression of interleukin-6, platelet-derived growth factor, transforming growth factor-β, and prostaglandin E2 did not correlate with tumor growth inhibition by aspirin, seven microRNAs showed altered expression in cancer cells in response to coincubation with platelets or addition of aspirin. Cells transfected with mir-4670-5p showed a significant increase in proliferation compared to negative control cells. Conclusions: Our study showed that platelets increased the proliferation of gastric cancer cells and that this increase was inhibited by antiplatelet antibody or aspirin. Mir-4670-5p may play an important role in these responses.",
author = "Jota Mikami and Yukinori Kurokawa and Tsuyoshi Takahashi and Yasuhiro Miyazaki and Makoto Yamasaki and Hiroshi Miyata and Kiyokazu Nakajima and Shuji Takiguchi and Masaki Mori and Yuichiro Doki",
year = "2016",
month = "7",
day = "1",
doi = "10.1007/s10120-015-0556-2",
language = "English",
volume = "19",
pages = "817--826",
journal = "Gastric Cancer",
issn = "1436-3291",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Antitumor effect of antiplatelet agents in gastric cancer cells

T2 - an in vivo and in vitro study

AU - Mikami, Jota

AU - Kurokawa, Yukinori

AU - Takahashi, Tsuyoshi

AU - Miyazaki, Yasuhiro

AU - Yamasaki, Makoto

AU - Miyata, Hiroshi

AU - Nakajima, Kiyokazu

AU - Takiguchi, Shuji

AU - Mori, Masaki

AU - Doki, Yuichiro

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Background: The antitumor effects of antiplatelet agents in gastric cancer cells are not well known. In this study, the possibility of gastric cancer treatment with an antiplatelet agent, mainly aspirin, was examined both in vivo and in vitro. Methods: For in vivo experiments, tumor-bearing mice were treated by an antiplatelet antibody or aspirin, and the tumor growth was compared. For in vitro experiments, human gastric cancer cell lines were used to confirm the cancer cell growth and inhibition by reducing the platelet count or using aspirin. We also examined several cytokines by using an ELISA assay and conducted microRNA microarray analysis of MKN-45 tumor cells to determine the influence of platelets or aspirin. Results: In vivo experiments showed that tumor growth was inhibited by halving the circulating platelet count by using an antiplatelet antibody or peroral daily aspirin. In vitro experiments showed that the proliferation rates of gastric cancer cell lines were increased after coincubation with platelets and that the effect was inhibited by aspirin. Although the expression of interleukin-6, platelet-derived growth factor, transforming growth factor-β, and prostaglandin E2 did not correlate with tumor growth inhibition by aspirin, seven microRNAs showed altered expression in cancer cells in response to coincubation with platelets or addition of aspirin. Cells transfected with mir-4670-5p showed a significant increase in proliferation compared to negative control cells. Conclusions: Our study showed that platelets increased the proliferation of gastric cancer cells and that this increase was inhibited by antiplatelet antibody or aspirin. Mir-4670-5p may play an important role in these responses.

AB - Background: The antitumor effects of antiplatelet agents in gastric cancer cells are not well known. In this study, the possibility of gastric cancer treatment with an antiplatelet agent, mainly aspirin, was examined both in vivo and in vitro. Methods: For in vivo experiments, tumor-bearing mice were treated by an antiplatelet antibody or aspirin, and the tumor growth was compared. For in vitro experiments, human gastric cancer cell lines were used to confirm the cancer cell growth and inhibition by reducing the platelet count or using aspirin. We also examined several cytokines by using an ELISA assay and conducted microRNA microarray analysis of MKN-45 tumor cells to determine the influence of platelets or aspirin. Results: In vivo experiments showed that tumor growth was inhibited by halving the circulating platelet count by using an antiplatelet antibody or peroral daily aspirin. In vitro experiments showed that the proliferation rates of gastric cancer cell lines were increased after coincubation with platelets and that the effect was inhibited by aspirin. Although the expression of interleukin-6, platelet-derived growth factor, transforming growth factor-β, and prostaglandin E2 did not correlate with tumor growth inhibition by aspirin, seven microRNAs showed altered expression in cancer cells in response to coincubation with platelets or addition of aspirin. Cells transfected with mir-4670-5p showed a significant increase in proliferation compared to negative control cells. Conclusions: Our study showed that platelets increased the proliferation of gastric cancer cells and that this increase was inhibited by antiplatelet antibody or aspirin. Mir-4670-5p may play an important role in these responses.

UR - http://www.scopus.com/inward/record.url?scp=84944937964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944937964&partnerID=8YFLogxK

U2 - 10.1007/s10120-015-0556-2

DO - 10.1007/s10120-015-0556-2

M3 - Article

C2 - 26486505

AN - SCOPUS:84944937964

VL - 19

SP - 817

EP - 826

JO - Gastric Cancer

JF - Gastric Cancer

SN - 1436-3291

IS - 3

ER -